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Abstract 
Background 
There is growing evidence that expanded supply of take-home naloxone to prevent opioid 
overdose deaths is needed. Potential routes for expansion of naloxone provision include through 
community pharmacies. The aim of this scoping review is to establish what is known about 
community pharmacy supply of naloxone, in light of unique challenges and opportunities present 
in pharmacy settings. 
Methods 
A scoping review methodology was employed using the six stage iterative process advocated by 
Arksey and O’ Malley (2005) and Levac et al., (2010). Searches used key words and terms such 
as ‘naloxone’; ‘overdose prevention/drug overdose/opiate overdose’; ‘community/retail 
pharmacy’; ‘pharmacist/pharmacy/community pharmacy/pharmaceutical services’; ‘professional 
practice/role’; ‘community care’; attitude of health personnel’; ‘training/supply/cost’). 
Appropriate search terms were selected for each database.   After initial exploratory searches, 
comprehensive searches were conducted with Cochrane Database of Systematic Reviews, 
Medline, Medline in Process, Embase, PsycINFO and CINAHL. Eligibility criteria centered on 
whether studies broadly described supply of naloxone in community pharmacy or had content 
relating to community pharmacy supply. 
Results 
The search identified 95 articles, of which 16 were related to pharmacy supply of naloxone. Five 
themes were presented after initial review of the data and consultation with the project Expert 
Group, and are; ‘Pharmacists Perceptions of Naloxone: Facilitators and Barriers’, ‘Patient 
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Populations: Identification and Recruitment’, ‘Supply Systems and Cost’, ‘Legal Issues’, and 
‘Training of Pharmacists and Community Pharmacy Naloxone Recipients’. 
Conclusion 
The community pharmacy based route for distribution of take home naloxone provision warrants 
further consideration and development. Existing strengths include a range of established supply 
models, and training curricula, few direct concerns regarding legal liability of pharmacists in the 
supply of naloxone (once legal supply systems have been established) and the wide range of 
potential identifiable patient populations, which include pain patients that may not be in contact 
with existing naloxone supply programmes. 
Key words 
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Introduction 
With the rising rates of opioid overdose deaths, naloxone has become one of a range of important 
strategies to address overdose (Straus, Ghitza, & Tai, 2013). Naloxone has been used for more 
than 40 years to reverse the effects of opioids in clinical and medical settings. Supply of 
naloxone for bystander administration is more recently becoming a well-established practice in 
the United States, Canada and the United Kingdom, with numerous studies and reviews 
confirming the feasibility, efficacy and cost-effectiveness of such programmes (Bennett, Bell, 
Tomedi, Hulsey, & Kral, 2011; Clark, Wilder, & Winstanley, 2014; Coffin & Sullivan, 2013; 
Giglio, Li, & DiMaggio, 2015; Walley, et al., 2013). 
 
Community based naloxone for overdose reversal was first implemented through community 
based initiatives established through peer-led advocacy work, with the Chicago Recovery 
Alliance prescribing and dispensing naloxone in an outreach model in 1998  (S. Maxwell, Bigg, 
Stanczykiewicz, & Carlberg-Racich, 2006).  Iinitial models of supply were based in systems that 
had a strong harm reduction focus and included peer-training through a developed training 
curriculum, and supply through peer-outreach services (S. Maxwell, et al., 2006). These early 
programmes, developed through advocacy from organisations oriented towards the needs of 
people who inject drugs (PWID), described hundreds of reports of successful reversals of opioid 
overdose in the first published programme descriptions (S. Maxwell, et al., 2006). 
 
In the past 15 years momentum has gathered to expand the reach take-home naloxone programs 
for opioid reversal within communities and in order to reach the diverse profile of potential 
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recipients. A shift in the nature of opioid dependence and mortality has been observed in some 
geographic regions over the same time period, from illicit opioids such as heroin to prescription 
opioids (J. Maxwell, 2011; Roxburgh & Burns, 2014). The increased role of prescription opioid 
medication in overdose fatalities, combined with the desire to expand the geographic reach of 
take-home naloxone initiatives has brought into sharp focus the opportunity for community 
pharmacy to become an important outlet and harm reduction partner in responding to concerns 
around opioid-related mortality. 
Although benefits of existing models of naloxone supply are clear, with the involvement of peers 
and programs embedded in services targeted to reach people who use and inject drugs, there may 
be a number of advantages to expanding the capacity of community pharmacy as a distribution 
point for take-home naloxone. Community pharmacies already supply medications to the general 
public and represent widely accessible health care sites in terms of geographic locations and 
opening hours. Many patients with an overdose risk may not be in contact with existing 
providers of take-home naloxone. Those not accessing naloxone through existing services may 
include pain patients using prescription opioids, in addition to those that choose to avoid services 
identified for people who use drugs due to concerns such as anonymity. In Scotland and England 
community pharmacy is already well integrated into the harm reduction provider network, with 
increasing engagement demonstrated over time (Matheson, Bond, & Tinelli, 2007; Sheridan, 
Manning, Ridge, Mayet, & Strang, 2007). 
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Community pharmacy also has some unique challenges when it comes to the supply of naloxone, 
in contrast with other existing programmes designed to meet the needs of people who use and 
inject drugs. Attitudes and knowledge in community pharmacy with respect to harm reduction 
measures vary greatly, with confidence and attitudes being potential barriers to access as seen in 
other aspects of substance use treatment (Butler & Sheridan, 2010; Hagemeier, Alamian, 
Murawski, & Pack, 2015). In a study from Scotland it was highlighted that some members of the 
public may not perceive pharmacies as a suitable location for harm reduction services (Gidman 
& Coomber, 2014). A study conducted in Tijuana, Mexico found that people who use and/or 
inject drugs may also show reluctance towards accessing harm reduction services in community 
pharmacies (Davidson, et al., 2012). Preliminary work in Indiana, USA, suggests that 
pharmacists appear interested in further training in the area of substance use and addiction 
treatment (Wenthur, et al., 2013). A further study of pharmacists in Estonia identified that not all 
pharmacists understand or support the provision of harm reduction (Vorobjov, Uusküla, Abel-
Ollo, Talu, & Jarlais, 2009). There is great variation in different countries with the involvement 
of community pharmacy in different aspects of harm reduction (Hammett, et al., 2014).  Levels 
of engagement with harm reduction more broadly vary between the US, Australia, Europe and 
the United Kingdom (UK), with supervised dosing of opioid substitution treatments for example 
not being common practice in the US, in contrast with being an accepted practice  model in 
Australia (Green, Dauria, Bratberg, Davis, & Walley, 2015; Watson & Hughes, 2012). Analyses 
of changing attitudes over time demonstrate that in Scotland, pharmacists have demonstrated a 
willingness to receive further training, which in turn appears to increase their participation in 
harm reduction activities (Matheson, Thiruvothiyur, Robertson, & Bond, 2015).  
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Given the potential to expand the provision of naloxone initiatives for bystander administration 
through community pharmacy, the aim of this scoping review was to understand what is 
currently known about community pharmacy supply of naloxone, with a particular focus on 
understanding current practice and supply models, and barriers that may need to be addressed in 
order to embed and optimize the expansion of naloxone supply through this community route. 
Methods 
Scoping review methodologies have become an increasingly popular and adopted approach 
across a variety of disciplines in recent years (Anderson, Allen, Peckham, & Goodwin, 2008; 
Arksey & O'Malley, 2005; Daudt, van Mossel, & Scott, 2013; Levac, Colquhoun, & O'Brien, 
2010; Pham, et al., 2014). For the purposes of this study, the definition of a scoping review as a 
type of research synthesis that aims to ‘map the literature on a particular topic or research area 
and provide an opportunity to identify key concepts; gaps in the research; and types and sources 
of evidence to inform practice, policymaking, and research’ (Daudt, et al., 2013) was employed.  
We chose to undertaken a scoping review as such reviews are particularly useful when a topic 
has not been extensively reviewed (Hidalgo Landa, Szabo, Le Brun, Owen, & Fletcher, 2011). 
Scoping reviews are additionally used as standalone project to provide a comprehensive 
descriptive overview of literature of a wide range of study designs and methodologies and do not 
engage in critical quality appraisal of individual studies or synthesise multiple study outcomes 
(Arksey and O’Malley, 2005; Brien et al., 2010).
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Scoping reviews utilise a rigorous and transparent method to identify and analyse all relevant 
literature on a particular topic (Arksey & O'Malley, 2005; Rumrill, Fitzgerald, & Merchant, 
2010). An iterative six stage process developed by Arksey and O’ Malley (2005) with later 
recommendations by Levac et al., (2010) was adhered to, and which consisted of (1) identifying 
the research question, (2) identifying relevant studies, (3) study selection, (4) charting the data, 
(5) collating, summarizing and reporting the results, and (6) an international expert advisory 
consultation exercise. The scoping review commenced with the establishment of a research team 
with addiction, harm reduction, pharmacy with  scoping and systematic review expertise (Levac, 
et al., 2010), who advised on the underpinning research question; ’What is known in the 
literature about community pharmacy supply of naloxone?’. The review concerned extant 
knowledge and gaps around supply of naloxone through community pharmacy. We defined 
community pharmacy supply of naloxone as programmes where pharmacists were directly 
supplying naloxone to people accessing retail or ‘community’ pharmacy settings. 
Search terms were agreed by the team, and the general search strategy is illustrated in Figure 1. 
The search terms for each group in the search strategy were chosen to be specific for each 
database. The initial search was implemented in July 2015 in National Drug and Alcohol 
Research Centre (NDARC) Library catalogue (which includes grey literature including policy 
documents and online reports), Project Cork, PubMed Clinical Queries, Scopus, (exploratory 
search with selected references downloaded for the purpose of clarifying search terms). 
Following exploratory searches, comprehensive searches were conducted in the Cochrane 
Database of Systematic Reviews, Medline, Medline in Process, Embase, PsycINFO and 
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CINAHL. The searches on all databases were limited to ‘Humans’, no limitations on language 
were applied. 
Insert Figure 1 about here 
Reference lists in articles retrieved were also manually searched by the team to identify any 
relevant studies, including grey literature, not captured. Members from the Expert group were 
also asked to identify key studies, including referral to extant grey literature. Citations were 
managed using the bibliographic software manager EndNote (Thomson Reuters, 2012) with 
duplicates removed manually. Eligibility criteria centered on whether studies broadly described 
supply of naloxone in community pharmacy or contained content directly relating to community 
pharmacy supply of naloxone. To enable the broadest picture of current knowledge and 
perceptions relating to naloxone in pharmacy settings we included commentary pieces and 
editorials, in addition to empirical data (See Table 1 for summary).  The title and abstract of each 
citation were screened by the lead author, where any doubt remained in terms of inclusion both 
authors reviewed the article (Levac et al., 2010).  All citations deemed relevant following this 
screening, were procured for review of the full text version. Studies were excluded at this stage if 
found not to meet the eligibility criteria. See Figure 2. 
Insert Figure 2 about here 
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Results 
The initial search identified 93 articles, of which 12 were identified to directly relate to 
community pharmacy supply of naloxone. A further four references were identified through the 
review process, including conference presentations and articles identified by the project Expert 
Group. Five themes were explored after initial review of the data and consultation with the 
scoping review Expert Group. The themes of (1) Pharmacists’ Perceptions of Naloxone: 
Facilitators and Barriers, (2) Patient Populations: Identification and Recruitment, (3) Supply 
Systems and Cost, (4) Legal Issues, (5) Training of Pharmacists and Community Pharmacy 
Naloxone Recipients. 
Pharmacist Perceptions of Naloxone: Facilitators and Barriers 
Three studies presented detail on perceptions of pharmacists on the supply of naloxone. One US 
study with in-depth interviews of community based pharmacy practitioners (n = 6) (Bailey & 
Wermeling, 2014) identified the potential for pharmacists to play a role in providing naloxone, 
educating patients and disseminating education within the community. Pharmacists indicated 
high levels of acceptance and support, with provider support viewed as instrumental in 
dispensing naloxone for overdose prevention. Where ethical considerations were raised (e.g. 
perceptions that naloxone supply may condone or support ongoing substances use) the 
pharmacists interviewed indicated that though it was conceivable that a pharmacist may refuse 
supply on ethical grounds, none of the pharmacists involved would do so once they understood 
the rationale for naloxone supply. Bailey and Wermeling (Bailey & Wermeling, 2014) also 
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reported that pharmacists described difficulties in financial and reimbursement issues despite 
gaining support from prescribers. 
Focus groups held with multidisciplinary members of the health care team (including 10 
physicians, nine nurses and four pharmacists) described a lack of consensus about who should be 
prescribed naloxone, with fear around offending patients and potential for increased risk 
behaviours in patients prescribed naloxone raised as potential barriers (Binswanger, et al., 2014). 
They described some level of discomfort with prescribing naloxone in contrast with other 
emergency outpatient medicines. This discomfort centered on fears of offending patients, 
patients potentially engaging in increased risk behaviours, complexities around naloxone and 
opioid prescribing decisions, treatment of a symptom rather than the problem of over prescribing 
and inadequate pain management, patient safety, overdoses and diversion of naloxone and the 
potential for seizures and cardiac arrests.  The medico-legal risks raised by Binswanger et al 
(2014) around the decision to supply naloxone as potentially identifying patients as ‘at risk’ may 
represent a barrier to supply, and may support the use of universal supply approaches for all 
patients exposed to opioids. 
Zaller et al., (Zaller, Yokell, Green, Gaggin, & Case, 2013) conducted in depth interviews with 
PWID (n = 21) and pharmacy staff (15 pharmacists and six technicians/interns) in Rhode Island, 
USA. This study highlighted overall that there was support for pharmacy based naloxone 
interventions. Some barriers were identified, such as misinformation, mismatch in perceived 
willingness to partake, interpersonal relationships between PWID and pharmacy staff, physical 
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restrictions in pharmacy settings, and concerns around staffing, time, space, reimbursement of 
time and cost. Study findings suggested that the misconceptions about willingness of both 
pharmacists and PWID to participate in pharmacy-based naloxone supply appeared unfounded, 
as both groups were willing to be involved in naloxone supply programs in pharmacy settings. 
 
Patient Populations: Identification of at-risk patient populations 
Potential patient populations 
Five studies presented detail on potential populations that may be appropriate for community 
pharmacy based naloxone interventions. An editorial by Wermeling (Wermeling, 2010) 
identified target patients groups 1) including anyone in receipt of a methadone prescription, 2) 
those on high doses of opioids (including high potency opioids), 3) patients with a recent opioid 
poisoning, 4) those with a suspected history of illicit or non-medical use of opioids, 5) those with 
concurrent use of opioids with antidepressants, benzodiazepines, or alcohol 6) those prescribed 
opioids with major organ dysfunction (renal, hepatic, cardiac, or pulmonary) and 7) patients 
released from opioid detoxification programs. This editorial also highlighted the requirement to 
train bystanders, family members or caregivers as first initial witnesses of overdose and most 
likely to respond. Green et al (Green, et al., 2015) in their case study described comprehensive 
eligibility for patient participation in Collaborative Pharmacy Practice Agreements (CPAN) in 
Figure 3, which were consistent with patient groups described by Wermeling (2010).  
 
Insert Figure 3 about here 
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Bailey and Wermeling, 2014 (Bailey & Wermeling, 2014) described interviews with six 
community based pharmacy providers who had collaborated with physician specialists in opioid 
abuse and overdose prevention for initiation of outpatient naloxone dispensing. They identified 
key patient groups in the United States (US) through prescription or medical records, 
prescription processing or provider screening tools as centering on patient demographics at the 
practice site and also high risk patient groups, namely (1) patients on high-dose opioids for 
chronic pain management or (2) patients at high risk of overdose secondary to abusing opioids, 
whether prescription or illicit. Collaborative care agreement between pharmacists and prescribers 
were advised to allow for initiation of discussion and prescribing of naloxone to patients without 
the need to go through another provider. This study highlighted that high-risk patients (those 
who currently abuse opioids or have a history of abuse) require additional proactive screening 
efforts and involvement of a drug and alcohol abuse specialists to refer patients best suited to 
outpatient naloxone.  
 
A separate study focusing on overdose prevention described a focus on pain medication 
prescribing including mandatory patient-prescriber agreements, use of a ‘pharmacy home’ (a 
single pharmacy for all dispensing), and supply of naloxone through the pharmacy home (Albert, 
et al., 2011). Data from Wilkes County (USA), the study location, identified a high frequency of 
overdose deaths in the home setting from pain medications, where family members could have 
intervened if they were aware of overdose signs and symptoms. This resulted in a programme of 
free-naloxone supply for patients receiving pain medications that met criteria for overdose risk 
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through community pharmacy. The criteria for eligibility for naloxone described by Albert et al 
(2011) are similar to those described above by Green et al (2015).  
 Risk groups for overdose  
In terms of the practical identification of patients, Binswanger et al (Binswanger, et al., 2014) 
conducted a qualitative study in Colorado (USA) using focus groups to unpack barriers at clinic 
and provider level (n=10) in the US. Clinical staff described uncertainty around who to prescribe 
naloxone to, concerns around offending patients and increased risk behaviours in patients 
prescribed naloxone along with logistical barriers for use in practice. Focus groups identified ‘at 
least nine risk groups for overdose including patients (1) prescribed high-dose opioids, long-
acting opioids, or benzodiazepines; (2) with a history of or predisposition to substance use 
disorders, or who also use alcohol or marijuana; … (3) with co-occurring mental health problems 
…(4) challenging or unstable social circumstances; (5) no access to ancillary pain services; (6) 
behavioural characteristics, such as poor coping skills or impulsivity; (7) unrealistic expectations 
about the efficacy of opioids to control pain; (8) inadequate attention to or understanding of safe 
use… and finally (9) patients with uncontrolled pain.’ Universal screening of all patients and 
inclusion of family members were discussed.  
 
Supply Systems and Cost  
 Supply Systems 
Thirteen papers, largely from the US and the UK, describe various aspects of pharmacy supply 
models for naloxone and associated cost implications. Many of these models have evolved 
through innovation to enable legal supply while reducing barriers to the expansion of naloxone 
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programmes. The main models of naloxone supply relating to community pharmacy are 
summarized in Table 2, ranging from traditional prescription supply models (i.e. a prescriber 
writes a prescription to an individual) to pharmacist-led patient screening, training and supply. In 
many settings multiple models are used, for example, a recent national survey in Scotland (N = 
709) found one third of pharmacies were currently willing and able to provide naloxone on 
prescription, with smaller numbers (n = 34, 4%) supplying naloxone through pharmacist 
prescribing or through patient group directives (n = 70, 9%) (Matheson, et al., 2015). There have 
been calls for pharmacists to take the lead in further developing operational models for 
pharmacies to supply naloxone (Wermeling, 2010), to build on what has been achieved in this 
area.  
 
Insert Table 1 about here  
 
Community pharmacy supply models were described to meet the needs of existing legal 
requirements for an individual prescriber to initiate supply to an individual patient, as opposed to 
necessarily representing ideal or optimized supply systems. Challenges and benefits were 
described with each of the models, generally with the least restrictive options (e.g. over-the-
counter (OTC) supply) allowing for the widest access, but having the greatest complications in 
terms of reimbursement for supply and need for pharmacist involvement (e.g. to identify and 
train patients). 
 
In the literature calls have been made for the rescheduling of naloxone to include pharmacy 
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(OTC) supply in Australia (Lenton, Dietze, Degenhardt, Darke, & Butler, 2009) and the United 
States (Beletsky, Rich, & Walley, 2012; Green, et al., 2015). In a commentary discussing how 
medications are identified to be appropriate for OTC supply, key considerations included 
whether the patient can accurately diagnose the condition that the medication is for, the 
possibility of adverse effects (including noting the perception of a moral hazard with naloxone 
supply), and the need for timeliness in medication supply (Fenichel, 2004). Fenichel also notes 
that due to complications with reimbursement with non-prescription products that over-the-
counter supply may adversely affect the supply though reduced affordability. 
Cost 
The cost for supplying naloxone through community pharmacist-initiated models, with respect to 
both the pharmaceutical product and pharmacist time are not well described in the existing 
literature, with most costs reported in models outside community pharmacy.  In a commercial 
setting such as retail pharmacy, high cost may impact on the feasibility, particularly as it is 
known that both chronic pain patients and PWID often have limited financial resources.  
 
Many current supply systems involve goodwill and may not represent the true cost. For example, 
there may not be a mechanism to reimburse pharmacists for time spent delivering overdose 
prevention training (Zaller, et al., 2013). Some clinics have been reported to be bearing the cost 
of the drug (naloxone) where funding is not available (Bailey & Wermeling, 2014), and identify 
that this may be a barrier to larger implementation and sustainability of programmes.  Where 
pharmacies are working with populations covered by some form of health insurance (for 
example, Medicaid in the US), arrangements have been made for the insurance to cover the cost 
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of the medication (Bailey & Wermeling, 2014).   In a US study Robinson & Wermeling note that 
public (e.g. Medicaid) and most private insurance plans cover the supply of the medication 
(naloxone), but usually do not include the nasal adapter (Robinson & Wermeling, 2014). One 
option to cover the cost of staff time is through recovering costs though remuneration for as part 
of delivering a ‘Screening, Brief Intervention, and Referral to Treatment’ (SBIRT) for a patient 
and a patient’s family on the use of the naloxone rescue kit (Robinson & Wermeling, 2014).  
 
Legal Issues 
Four studies discussed legal issues pertaining to pharmacy naloxone supply. Several legal issues 
were addressed by innovators of naloxone programmes in the implementation of community 
naloxone supply. Pharmacy groups have identified ways to address the need for naloxone to have 
a prescription though standing orders and different practice agreements and group directives (see 
Table 2 for further details).  Two studies discussing pharmacy supply of naloxone in the UK 
described legal changes that preceded the programme establishment that allowed members of the 
public to administer naloxone, adding naloxone to the list of medications that can be 
administered by the public for the purposes of saving a life in an emergency (Laird & Hunter, 
2014; Yates, 2015). 
 
A concern directly related to community pharmacist practice is medico-legal issues with patient 
selection. Medico-legal concerns associated with identifying patients receiving opioids as 
medically ‘at risk’ was raised by a focus group of health care professionals members, suggesting 
that raising the question of naloxone supply also raises the concern that the patient may be at risk 
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if continued on opioids (Binswanger, et al., 2014). Taking a more comprehensive approach to 
offering naloxone to all patients on opioids was proposed as one way to reduce this legal 
concern, and also reduce the perception of stigma from the patients’ point of view (Binswanger, 
et al., 2014). How this may unfold in community pharmacy practice has not yet been explored, 
but may support the practice of more universal supply of naloxone and within the context of low 
threshold community supply routes, as was proposed by pharmacists in this study.  
 
Finally, the supply of naloxone to a third party was identified as a potential legal issue for 
pharmacists. It was identified that although naloxone may be logically supplied to third parties 
who are trained to administer naloxone, third parties supply is not legal in all US states  (Bailey 
& Wermeling, 2014). 
 
Training of Pharmacists and Community Pharmacy Naloxone Recipients 
Three articles described training audiences (pharmacist and naloxone recipients), training 
processes and curricula directly pertaining to pharmacy practice. Riner et al (Riner & 
Wermeling, 2014) describe a protocol providing guidance to pharmacists in Kentucky (USA) 
with regard to education of patients and their families in overdose prevention, recognition and 
response. Bailey and Wermeling (Bailey & Wermeling, 2014) described training pharmacists 
and pharmacy staff in administration of naloxone products (intranasal (IN) atomizer or 
intramuscular (IM) injection and the patient instructions).  Both in-house training programs 
(developed by pharmacies themselves) and formal training (for example 
www.prescribetoprevent.org) were documented (Bailey & Wermeling, 2014). Educational 
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competencies generally center on use of emergency numbers (e.g. 911 in the US) rescue 
breathing, checking for pulse, preparing the naloxone product for administration, assessing for 
response and repeating dose if required (Bailey & Wermeling, 2014). This study advocated the 
training of patients and third parties (i.e. their family members) at time of naloxone dispensing. 
Additional supports often include video materials which ensure that those with low literacy 
understood the information around overdose prevention, recognition and response (Bailey & 
Wermeling, 2014).  
 
In terms of pharmacists training naloxone recipients (lay people), one pilot study of 18 
pharmacies in Glasgow, Scotland trained 26 pharmacists and 15 support staff who then provided 
training and naloxone to people inject drugs through a patient group directive supply model 
(Laird & Hunter, 2014). This pilot work found that it was feasible and acceptable to staff in 
community pharmacy settings.  
 
Discussion 
The review scoped the extant available literature around what is known about community 
pharmacy supply of naloxone. We identified a foundation of work which can inform the 
direction of provision of naloxone to diverse patient groups and their relatives accessing 
community pharmacy settings. A range of pharmacy specific supply models and logistical 
barriers were identified. Further work to address these barriers may help harness to capacity of 
community pharmacy to extend and enhance the reach of take-home naloxone to the diverse 
patients groups at risk of opioid overdose.  The review identified a number of strengths including 
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a range of established supply models that may be used depending on the setting, existing training 
curricula, and identification of patient populations (e.g., people prescribed opioids for chronic 
pain) that may not access naloxone through programs outside of a pharmacy setting. 
 
Potential challenges to address with health professionals include concerns around a ‘moral 
hazard’ (Fenichel, 2004), or the risk that the perception of a naloxone as a safety-net might 
increase substance use or inappropriate self-medication for pain patients. One study conducted in 
the UK found reductions in heroin use following naloxone training (Gaston, Best, Manning, & 
Day, 2009). This suggests such concerns may be unfounded, and addressing these unfounded 
perceptions may be important as part of pharmacist education.  
 
While consistent ‘risk groups’ of people were identified in this review, concerns that identifying 
‘at risk’ patients to supply naloxone to may create personal and public stigma, and result in 
reluctance to supply naloxone and/or opioids due to medico-legal risks must be addressed. 
Further work may help to resolve these issues and explore the feasibility and cost-effectiveness 
of proposed universal supply approaches that avoid identifying, and potentially stigmatizing or 
otherwise identifying specific patient groups who are ‘at risk’. This review identified that 
pharmacists appeared to support more universal supply strategies. Notwithstanding concerns 
around targeting specific patient groups, community pharmacists have access to patients’ 
medication histories, and are optimally positioned to identify those that meet some established 
risk factors such as poly-pharmacy and higher opioid doses.  
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The existing literature on naloxone with respect to legal issues for pharmacists is limited.  Few 
studies directly inform if concerns exist regarding legal liability of community pharmacists in the 
supply of naloxone. In most countries naloxone is still a prescription only medication, meaning 
that it can only be administered by a person operating under a legal prescription, and prescribing 
usually requires that the prescriber has established a relationship with the patient (Burris, 
Norland, & Edlin, 2001), though other numerous models are described including standing orders 
and OTC supply were identified through this review.  
 
Challenges identified with supply systems include gaining clarity around payment in different 
types of health care systems, notably with OTC supply. These issues are particularly timely in 
Australia where the Therapeutic Goods Administration have announced the decision to 
reschedule naloxone to an over-the-counter (pharmacist only) medication in February 2016 
(Therapeutic Goods Administration, 2015). This will mean for patients receiving subsidies on 
prescription medications, the cost of OTC supply will almost certainly substantially exceed the 
cost (currently AUD$6.10) for a subsidised prescription. This may mean that the impact of 
greater availability of naloxone through OTC access may not be realized.  Reports of medication 
cost in the US vary with US$15 per injectable naloxone kit; and around US$25-$35 per 
intranasal naloxone kit (Coffin & Sullivan, 2013; Doe-Simkins, et al., 2014; Robinson & 
Wermeling, 2014). Some programmes have additionally factored in around US$10 for staff time 
per kit (Coffin & Sullivan, 2013).  More recently even higher prices have been reported (for 
example US$60-$80 for a 2 dose rescue kit) (Davis, Carr, Southwell, & Beletsky, 2015), though 
even at much higher prices naloxone supply to heroin users has been demonstrated to be cost 
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effective for reversal of heroin overdose (Coffin & Sullivan, 2013). The question remains as to 
how this cost can be covered, particularly in commercial retail settings such as community 
pharmacy.  
 
Finally, in terms of the last theme of training, numerous studies have demonstrated that lay-
persons can be effectively trained in a range of settings [see (Clark, et al., 2014) for review], 
though we only identified pilot studies examining feasibility and not effectiveness of naloxone 
training delivered by pharmacists. Research is needed to confirm the efficacy of a pharmacy-led 
brief intervention for naloxone and overdose prevention, given pharmacists are generally not 
experts training in how to respond to drug overdoses. Numerous studies also advocate the 
importance of naloxone prescribing within an overall overdose management programme which 
includes resuscitation training and cardiopulmonary resuscitation (CPR), though the feasibility of 
overall overdose management programs with CPR in community pharmacy programs may be 
questioned (Dong, et al., 2012; George & Moreira, 2008; Leece, et al., 2013; Piper, et al., 2007).  
 
While earlier versions of recipient training programs were up to eight hours in duration (Doe-
Simkins, Walley, Epstein, & Moyer, 2009; Seal, et al., 2005), more recently brief training (5-10 
minutes) appeared sufficient to improve comfort and ability in responding to overdose (Behar, 
Santos, Wheeler, Rowe, & Coffin, 2015; Liu, Mazur-Routsolias, Lu, & Aks, 2013). Five to ten 
minute training would be ideally suited to community pharmacy settings where time is an often 
cited barrier when implementing new services (Firth, Todd, & Bambra, 2015; Mansoor, Krass, 
Costa, & Aslani, 2015; Watson & Hughes, 2012). Further work may address the feasibility of 
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training in a community pharmacy setting, including address previously identified concerns 
around privacy in these settings (Saramunee, et al., 2014). One study among substance using 
participants found few behavioral differences between trained and untrained overdose rescuers, 
possibly due to high levels of baseline knowledge due to informal training and information 
sharing among untrained participants (Doe-Simkins, et al., 2014). This finding may suggest for 
some patient groups training is less critical.    
 
As naloxone supply in pharmacy expands it remains to be established as to the most effective 
way to upskill the diverse workforce of pharmacy settings. Mayet et al., (Mayet, Manning, 
Williams, Loaring, & Strang, 2011) examined training drug and alcohol clinicians and found 
modest success of the ‘cascade method’ in training activity aimed at large clinician workforces. 
This method utilises trained clinicians to then train other clinicians and drug users and requires 
further refinement for applicability in naloxone programming. Challenges in using this method 
centered on knowledge gaps, lack of confidence, formulation of naloxone, and requirement for 
local leads. Training modalities such as online training www.getnaloxonenow.org  ("Site Offers 
Free Online Naloxone Training," 2015) for emergency practitioners and laypeople significantly 
increased knowledge around opioid overdose and confidence in appropriate responses with 
naloxone, and online training may represent a practical mode of training for pharmacists. 
 
Some gaps in the literature were identified. Although studies have captured pharmacists’ 
perceptions, the studies only represent a small number of pharmacists (25 pharmacists in total, all 
from the United States). Further work may help understand how well the support and concerns 
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expressed in these studies relating to naloxone are echoed by other pharmacists, particularly 
pharmacists from different countries or different practice settings. Understanding the range of 
potential issues and barriers may facilitate implementation, in addition to fostering ongoing 
training opportunities, which appears to be related to increased involvement with other harm 
reduction programs (Matheson, et al., 2015). Given the relatively early stage of research in terms 
of pharmacy naloxone supply, the literature reviewed included editorials and commentaries, 
which add to the understanding of attitudes and perceptions around naloxone, but are limited in 
their scientific rigor. Large empirical studies demonstrating effectiveness of community 
pharmacy training of recipients (given that research on efficacy of naloxone training has largely 
examined training by peers or drug and alcohol experts) and of pharmacy naloxone supply more 
broadly were not identified. Further, the acceptability and affordability of pharmacy supply for 
people who inject drugs should be explored. Finally, it should be acknowledged with the 
proposal to supply naloxone to chronic pain patients that gaps also exist in the both the 
acceptability of naloxone supply for pain patients, and the cost effectiveness of take-home 
naloxone for patients receiving opioids for pain given the large population and relatively lower 
overdose frequency.  
It should be acknowledged that limitations may also exist resulting from the scoping review 
methodology itself. While we aimed to be comprehensive in our approach, there is the possibility 
that not all relevant work was identified by the searches or databases used. In addition, scoping 
reviews do not include an assessment of study quality as the focus is on covering the range of 
work that informs the topic rather than limiting the work to studies that meet particular standards 
of scientific rigour.  
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Conclusion  
Provision of naloxone for bystander administration to prevent opioid overdose deaths appears 
increasingly feasible and warranted given the rise in rates of overdose deaths. Community 
pharmacy supply of take home naloxone warrants further development and consideration, in 
light of general support from the small number of pharmacists included in research so far. 
Barriers including cost and remuneration for community pharmacists’ time, and how pharmacists 
may effectively identify and train naloxone recipients were identified in this review.  In 
summary, some work has been done to lay the groundwork for larger scale implementation of 
naloxone supply in pharmacy. Future studies may help to understand and resolve barriers to 
support expansion of pharmacy supply models in different geographical regions.  
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Figure 1 Search Terms and Strategy 
1. Naloxone 
2. Overdose prevention or drug overdose or opiate overdose 
3. community pharmac* or retail pharmac* or pharmacist* or pharmacy or community pharmacy 
services or pharmaceutical services or professional practice or professional role or community care or 
attitude of health personnel 
4. training or supply or cost 
5. 3 or 4 
6. buprenorphine or buprenorphine-naloxone or buprenorphine adj naloxone 
7. 1 and 2 and 5 
8. 7 not 6 
Databases were searched using the appropriate subject headings in each database and/or keywords or 
textwords for the above search groups: 
 
Sample  Search (Medline (via Ovid platform) searched on 21/7/15 
# Searches Results 
1 *Naloxone/ 6699 
2 exp Drug Overdose/ 8002 
3 "overdose prevention".tw. 102 
4 "opiate overdose".tw. 119 
5 or/2-4 8061 
6 "community pharmac*".tw. 3144 
7 "retail pharmac*".tw. 354 
8 exp Pharmaceutical Services/ or exp "Attitude of Health Personnel"/ or exp Pharmacists/ or exp 
Community Pharmacy Services/ or exp Professional Role/ 212463 
9 pharmacist*.tw. 18811 
10 pharmacy.tw. 25009 
11 "community care".tw. 3141 
12 or/6-11 234448 
13 exp Inservice Training/ 25011 
14 training.tw. 238913 
15 supply.tw. 89976 
16 "Costs and Cost Analysis"/ 43221 
17 or/13-16 386504 
18 12 or 17 598633 
19 buprenorphine.ti. 2685 
20 buprenorphine-naloxone.ti. 184 
21 (buprenorphine adj naloxone).ti. 184 
22 or/19-21 2685 
23 1 and 5 and 18 43 
24 23 not 22 42 
25 limit 24 to (humans and (evaluation studies or journal article or meta analysis or randomized 
controlled trial or "review" or systematic reviews)) 40 
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Figure 2 Flowchart for inclusion and exclusion of literature  
 
 
 
 
 
143 articles identified through database 
searching (50 duplicates removed)  
 93 articles screened for inclusion criteria 
Final number of articles charted   
n = 16 
6 other records 
included (additional 
papers and 
conference 
presentations) 
54 full-text articles 
retrieved  
44 records excluded for lack 
of relevance specificically to 
pharmacy practice 
39 excluded on 
abstract review 
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Figure 3 Eligibility for patient participation in Collaborative Pharmacy Practice 
Agreements (CPAN) 
▪ Voluntarily request;  
▪ Recipient of emergency medical care for acute opioid poisoning;  
▪ Suspected illicit or nonmedical opioid user ; 
▪ High dose opioid prescription (>100 morphine mg equivalents daily);  
▪ Methadone prescription to opioid naïve patient;  
▪ Dispensed an opioid prescription and:  
▪ History of smoking;  
▪ COPD;  
▪ Respiratory illness or obstruction;  
▪ Renal dysfunction or hepatic disease;  
▪ Known or suspected concurrent alcohol abuse;  
▪ Concurrent benzodiazepine prescription;  
▪ Concurrent SSRI or TCA anti-depressant prescription;  
▪ Recently released prisoners from a correctional facility; 
▪ Released from opioid detoxification or mandatory abstinence programme;  
▪ Patients entering a methadone maintenance treatment programme; and  
▪Patients that may have difficulty accessing emergency medical services. 
(Green, Dauria, Bratberg, Davis, & Walley, 2015, p4) 
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Table 1 - Summary of review literature 
Authors Year Method Themes 
Albert, S., et al. 2011 Preliminary findings from a community based naloxone program  Populations, Supply systems and cost 
Bailey, A.  & Wermeling, 
D.  
2014 Qualitative interviews with pharmacists  
Perceptions, Populations, Supply 
systems and cost, Legal issues, 
Training 
Beletsky, L. et al..  2012 Commentary on naloxone supply Supply systems and cost 
Binswanger, I. et al  2014 Qualitative interviews with primary care staff (including pharmacists) Perceptions, Populations, legal issues 
Fenichel, R. R.   2004 Commentary on assessing appropriateness of drug for over the counter supply Supply systems and cost 
Green, T. C. et al 2015 Case studies of two supply models from different US jurisdictions Populations, Supply systems and cost 
Hill, D & Mcauley A. 2012 
Quantitative survey views on naloxone provision of service providers, service-
users and family/friends  
Supply systems and cost 
Laird, A., & Hunter, C.  2014 Findings from a pilot program of pharmacy naloxone supply 
Legal issues, supply systems and cost, 
training 
Lenton, S. et al. 2009 Letter to the editor Supply systems and cost, legal issues 
Matheson, C. et al.  2015 
National survey of pharmacists (repeated 4 times over 2 decades). More recent 
survey  included questions on naloxone 
Supply systems and cost 
Riner, E., & Wermeling, 
D. 
2014 Describes protocol in development for pharmacists naloxone supply Training 
Robinson, A. & 
Wermeling, D. 
2014 Review of information about naloxone focusing on intranasal route Supply systems and cost 
Traynor, K. 2014 Program description in news section of journal Supply systems 
Wermeling, D. P.   2010 Editorial Populations, Supply systems and cost 
Yates, J. 2015 Program description and interim report of pilot study with pharmacy supply Legal issues, 
Zaller, N. et al. 2013 
Semi-structured interviews with individuals who inject drugs and pharmacy 
staff 
Perceptions, supply systems and cost 
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Table 2 - Pharmacy models of naloxone supply 
Supply model Benefits Disadvantages Examples described in the literature 
Traditional supply model 
(i.e. one prescriber supplies 
for an individual patients 
though a standard 
consultation, with 
subsequent and pharmacy 
supply) 
Doctors can identify appropriate 
patients in medical settings. The 
use of usual supply mechanisms 
allows use of reimbursement 
models (eg government 
subsidized prescriptions or 
health insurance coverage). 
Training may occur off-site, 
being provided in the medical 
setting. 
Relies on access to prescriber, limits 
opportunities for other parties to 
initiate supply. Not all people who 
many benefit from naloxone are in 
contact with prescribers. 
Large US metropolitan cities including Boston, 
Seattle and Pittsburgh, examples of programmes 
where prescriptions are included on Medicaid 
Formulary (Bailey & Wermeling, 2014) 
Wilkes country ‘Project Lazarus’, prescriber of 
pain medications shows  a video to train patient 
and patient is able access free naloxone at 
designated pharmacy. (Albert, et al., 2011) 
Pharmacists initiated (e.g. 
pharmacist has prescriptive 
authority) 
Easier to initiate in pharmacy 
setting, pharmacist can identify 
and proactively discuss with 
patients. 
May be challenges in pharmacists 
identifying appropriate patients. 
Less clear how pharmacists may be 
reimbursed. Not all pharmacists 
may have prescribing rights. 
Training may need to be provided in 
pharmacy. 
One of six pharmacists interviewed by Bailey and 
Wermeling (2014) had pharmacist prescriptive 
authority and was able to proactively seek out 
patients  (Bailey & Wermeling, 2014). A national 
survey identified 4% of pharmacist can prescribe 
naloxone (Matheson, et al., 2015). 
Over the counter pharmacy 
supply 
The least restrictive model of 
pharmacy supply. Takes 
advantage of the accessibility of 
community pharmacy as a 
primary health care setting. 
Enables other non-medical 
services (e.g. support services 
for people who use drugs) to 
directly refer patients with no 
administrative barriers to supply. 
May limit ability for reimbursement 
of medication costs. Requires legal 
changes in many locations. Training 
may need to be provided in 
pharmacy setting if patients have 
not already received training. 
Numerous papers called for over-the-counter 
supply of naloxone (eg (Lenton, et al., 2009)), 
though no descriptions of an OTC supply model 
were found in the literature. 
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Supply model Benefits Disadvantages Examples described in the literature 
Standing order – naloxone is 
prescribed using a 
prewritten medication order 
so a health care professional  
(or class of healthcare 
professionals) can supply 
naloxone in clearly defined 
circumstances 
Removes barrier for individual 
prescription. Usually does not 
require legislative change. May 
assist implementation of 
programmes where collaborative 
practice agreements only permit 
pharmacists to dispense 
medication to individuals that 
are established patients of the 
prescriber.(Green, et al., 2015) 
Still requires a system to be 
established and administratively 
may be burdensome. Training may 
need to be provided in pharmacy. 
In a programme description from Massachusetts 
the medical director serves as the single prescriber 
to all community-based naloxone recipients 
(Green, et al., 2015) 
Collaborative practice 
agreement (CPA). Single 
prescriber authorizes 
multiple pharmacies to 
supply naloxone. CPAs 
permit a pharmacist to work 
in collaboration with a 
prescriber for the purpose of 
drug therapy management 
within an agreed protocol. 
Removes need for individual 
prescription being required, 
allowing access to a broader 
number of people. In some 
jurisdictions pharmacists can 
initiate supply under a CPA. 
In some jurisdictions it is required 
that the prescriber has a relationship 
with the patient. Training may need 
to be provided in pharmacy. 
48 states permit pharmacists to enter into CPAs 
with prescribers to manage patient pharmaceutical 
care, and at least 21 states permit pharmacists to 
initiate medication under a CPA (Green, et al., 
2015; Traynor, 2014) 
Patient Group Directions 
(PGDs) are written 
instructions for the supply or 
administration of medicines 
to groups of patients who 
may not be individually 
identified before 
presentation for treatment.  
Removes need for individual 
prescription 
Training may need to be provided in 
pharmacy. Method for payment 
unclear, and may not translate to 
community pharmacy setting 
Examples of patient group directions exist in the 
NHS in the UK (Hill & McAuley, 2012; Laird & 
Hunter, 2014; Matheson, et al., 2015). These 
models involve pharmacist supply, though they 
are usually operating within health services as 
opposed to community pharmacy. 
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